Drug Trial Radar · NCT05382312
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
127
Actual
Start
Jul 26, 2022
Primary completion
May 27, 2025
Study completion May 27, 2025
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Click-TB Consortium
- First posted
- May 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study measured the early bactericidal activity (EBA), safety, tolerability and pharmacokinetics of GSK3036656 in combination with either delamanid, bedaquiline or BTZ-043 and delamanid in combination with bedaquiline or standard of care, for 14 days, in participants with newly diagnosed sputum smear positive drug-sensitive pulmonary tuberculosis. Participants reverted to the standard treatment (RIFAFOUR e-275) once the study treatment (Day 1 to Day 14) was completed.
Conditions
- Tuberculosis
Interventions
GSK3036656Drug
GSK3036656 was administered.
BedaquilineDrug
Bedaquiline was administered.
DelamanidDrug
Delamanid was administered.
RIFAFOUR e-275Drug
RIFAFOUR e-275 was administered.
BTZ-043Drug
BTZ-043 was administered.
PretomanidDrug
Pretomanid was administered.
LinezolidDrug
Linezolid was administered.
MoxifloxacinDrug
Moxifloxacin was administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in log10 Colony Forming Units (CFU) of Mycobacterium Tuberculosis (MTB)Time frame: At Baseline and at days 1, 2, 3, 4, 6, 8, 10, 12 and 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Bellville, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.